GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

Not Applicable

• Conditions: Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
• Interventions: Drug: Placebo; Drug: Liraglutide

• Registration Number: NCT01451905
• Lead Sponsor: University Hospital, Gentofte, Copenhagen

Brief Summary

To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08
• Study First Submitted: 2011-10-11
• Study First Submitted QC: 2011-10-11
• Study First Posted: 2011-10-14
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-20
• Last Update Posted: 2012-06-21
• Primary Completion: 2012-12
• Study Completion: 2012-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Psoriasis	Liraglutide	-

Primary Outcome Measures

Name	Time	Method
Changes in PASI and DLQI	2 months

Trial Locations

Locations (1)

Gentofte Hospital; 🇩🇰 Hellerup, Denmark